Overall survival by race in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide.
Megan McNamara(Duke Medical Center), Stephen J. Freedland(Cedars-Sinai Medical Center), Daniel J. George(Duke University), Jack Mardekian(Pfizer (United States)), Onur Başer(STATinMED (United States)), Krishnan Ramaswamy(Pfizer (United States)), Ahong Huang(STATinMED (United States)), Neil M. Schultz(Astellas Pharma (United States)), Li Wang(University of Science and Technology of China), Stanislav Lechpammer(Pfizer (United States))
Cited by 36
Related Papers
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
|New England Journal of Medicine|2020|442